|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mutch DG and Prat J: 2014 FIGO staging for
ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol.
133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nodin B, Zendehrokh N, Sundström M and
Jirström K: Clinicopathological correlates and prognostic
significance of KRAS mutation status in a pooled prospective cohort
of epithelial ovarian cancer. Diagn Pathol. 8:1062013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei
Y, Li Y, Yang Q, Liu J, Wei JJ, et al: miR-145 inhibits tumor
growth and metastasis by targeting metadherin in high-grade serous
ovarian carcinoma. Oncotarget. 5:10816–10829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pereira A, Magrina JF, Magtibay PM,
Pérez-Medina T, Fernández A and Peregrin I: The impact of
peritoneal metastases in epithelial ovarian cancer with positive
nodes. Int J Gynecol Cancer. 21:1375–1379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Candido-dos-Reis FJ, Song H, Goode EL,
Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington
P, Ramus SJ, et al: Germline mutation in BRCA1 or BRCA2 and
ten-year survival for women diagnosed with epithelial ovarian
cancer. Clin Cancer Res. 21:652–657. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bi L, Yang Q, Yuan J, Miao Q, Duan L, Li F
and Wang S: MicroRNA-127-3p acts as a tumor suppressor in
epithelial ovarian cancer by regulating the BAG5 gene. Oncol Rep.
36:2563–2570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moss EG: MicroRNAs: Hidden in the genome.
Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen L, Zhang F, Sheng XG, Zhang SQ, Chen
YT and Liu BW: MicroRNA-106a regulates phosphatase and tensin
homologue expression and promotes the proliferation and invasion of
ovarian cancer cells. Oncol Rep. 36:2135–2141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang T, Li L, Cheng Y, Ren C and Zhang G:
MicroRNA-194 promotes the growth, migration, and invasion of
ovarian carcinoma cells by targeting protein tyrosine phosphatase
nonreceptor type 12. Onco Targets Ther. 9:4307–4315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin ZY, Chen G, Zhang YQ, He HC, Liang YX,
Ye JH, Liang YK, Mo RJ, Lu JM, Zhuo YJ, et al: MicroRNA-30d
promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA
pathway and predicts aggressive outcome in prostate cancer. Mol
Cancer. 16:482017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cong J, Liu R, Wang X, Wang J, Wang H and
Hou J: Low miR-498 expression levels are associated with poor
prognosis in ovarian cancer. Eur Rev Med Pharmacol Sci.
19:4762–4765. 2015.PubMed/NCBI
|
|
16
|
Zhou X, Yue Y, Wang R, Gong B and Duan Z:
MicroRNA-145 inhibits tumorigenesis and invasion of cervical cancer
stem cells. Int J Oncol. 50:853–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li C, Lu S and Shi Y: MicroRNA-187
promotes growth and metastasis of gastric cancer by inhibiting
FOXA2. Oncol Rep. 37:1747–1755. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W,
Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell
lung cancer and promotes lung cancer cell growth in vitro and in
vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
|
|
19
|
Guo J, Cao R, Yu X, Xiao Z and Chen Z:
MicroRNA-223-3p inhibits human bladder cancer cell migration and
invasion. Tumour Biol. 39:10104283176916782017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin L, Zhang Y, Lin J, Shentu Y and Xie X:
MicroRNA-455 regulates migration and invasion of human
hepatocellular carcinoma by targeting Runx2. Oncol Rep.
36:3325–3332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu J, Zhang J, Li Y, Wang L, Sui B and
Dai D: miR-455-5p acts as a novel tumor suppressor in gastric
cancer by down-regulating RAB18. Gene. 592:308–315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li YJ, Ping C, Tang J and Zhang W:
MicroRNA-455 suppresses non-small cell lung cancer through
targeting ZEB1. Cell Biol Int. 40:621–628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Y, Dong Q and Wang E: MicroRNA-320
inhibits invasion and induces apoptosis by targeting CRKL and
inhibiting ERK and AKT signaling in gastric cancer cells. Onco
Targets Ther. 10:1049–1058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen Y, Ye YF, Ruan LW, Bao L, Wu MW and
Zhou Y: Inhibition of miR-660-5p expression suppresses tumor
development and metastasis in human breast cancer. Genet Mol Res.
16:2017. View Article : Google Scholar
|
|
27
|
Zhuo HC, Song YF, Ye J, Lai GX and Liu DL:
MicroRNA-154 functions as a tumor suppressor and directly targets
HMGA2 in human non-small cell lung cancer. Genet Mol Res. 15:2016.
View Article : Google Scholar
|
|
28
|
Xiaohong Z, Lichun F, Na X, Kejian Z,
Xiaolan X and Shaosheng W: MiR-203 promotes the growth and
migration of ovarian cancer cells by enhancing glycolytic pathway.
Tumour Biol. 37:14989–14997. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao X, Zhou Y, Chen YU and Yu F: miR-494
inhibits ovarian cancer cell proliferation and promotes apoptosis
by targeting FGFR2. Oncol Lett. 11:4245–4251. 2016.PubMed/NCBI
|
|
30
|
Chai J, Wang S, Han D, Dong W, Xie C and
Guo H: MicroRNA-455 inhibits proliferation and invasion of
colorectal cancer by targeting RAF proto-oncogene
serine/threonine-protein kinase. Tumour Biol. 36:1313–1321. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng CM, Shiah SG, Huang CC, Hsiao JR and
Chang JY: Up-regulation of miR-455-5p by the TGF-β-SMAD signalling
axis promotes the proliferation of oral squamous cancer cells by
targeting UBE2B. J Pathol. 240:38–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y,
Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an
oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiao L and Wong BC: Role of Notch
signaling in colorectal cancer. Carcinogenesis. 30:1979–1986. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Purow BW, Haque RM, Noel MW, Su Q, Burdick
MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, et al:
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1,
is critical for glioma cell survival and proliferation. Cancer Res.
65:2353–2363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong Y, Shen S, Zhou Y, Mao F, Lin Y,
Guan J, Xu Y, Zhang S, Liu X and Sun Q: NOTCH1 is a poor prognostic
factor for breast cancer and is associated with breast cancer stem
cells. Onco Targets Ther. 9:6865–6871. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chu D, Zhou Y, Zhang Z, Li Y, Li J, Zheng
J, Zhang H, Zhao Q, Wang W, Wang R and Ji G: Notch1 expression,
which is related to p65 Status, is an independent predictor of
prognosis in colorectal cancer. Clin Cancer Res. 17:5686–5694.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sima J, Zhu MY, Ai Q, Zhang C, Yao ZY,
Huang QB and Zhang X: Expression analysis of NOTCH1/HES1/PTEN
signaling pathway in invasive bladder transitional cell carcinoma.
Zhonghua Yi Xue Za Zhi. 92:964–967. 2012.(In Chinese). PubMed/NCBI
|
|
38
|
Zhang H, Wang X, Xu J and Sun Y: Notch1
activation is a poor prognostic factor in patients with gastric
cancer. Br J Cancer. 110:2283–2290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang
C, Zhu M, Zhang Y, Wang B, Ni D, et al: High-level expression of
Notch1 increased the risk of metastasis in T1 stage clear cell
renal cell carcinoma. PLoS One. 7:e350222012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ogawa R, Ishiguro H, Kimura M, Funahashi
H, Wakasugi T, Ando T, Shiozaki M and Takeyama H: NOTCH1 expression
predicts patient prognosis in esophageal squamous cell cancer. Eur
Surg Res. 51:101–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Won HY, Lee JY, Shin DH, Park JH, Nam JS,
Kim HC and Kong G: Loss of Mel-18 enhances breast cancer stem cell
activity and tumorigenicity through activating Notch signaling
mediated by the Wnt/TCF pathway. FASEB J. 26:5002–5013. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sharma A, Paranjape AN, Rangarajan A and
Dighe RR: A monoclonal antibody against human Notch1 ligand-binding
domain depletes subpopulation of putative breast cancer stem-like
cells. Mol Cancer Ther. 11:77–86. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Al-Hussaini H, Subramanyam D, Reedijk M
and Sridhar SS: Notch signaling pathway as a therapeutic target in
breast cancer. Mol Cancer Ther. 10:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang M, Wang J, Wang L, Wu L and Xin X:
Notch1 expression correlates with tumor differentiation status in
ovarian carcinoma. Med Oncol. 27:1329–1335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Alniaimi AN, Demorest-Hayes K, Alexander
VM, Seo S, Yang D and Rose S: Increased Notch1 expression is
associated with poor overall survival in patients with ovarian
cancer. Int J Gynecol Cancer. 25:208–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rose SL, Kunnimalaiyaan M, Drenzek J and
Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol
Oncol. 117:130–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liang T, Guo Q, Li L, Cheng Y, Ren C and
Zhang G: MicroRNA-433 inhibits migration and invasion of ovarian
cancer cells via targeting Notch1. Neoplasma. 63:696–704. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao Y, Rankin GO, Tu Y and Chen YC:
Theaflavin-3, 3′-digallate decreases human ovarian carcinoma
OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not
via MAPK pathways. Int J Oncol. 48:281–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zou W, Ma X, Hua W, Chen B and Cai G:
Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian
cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB
pathway. Oncol Rep. 34:3256–3263. 2015. View Article : Google Scholar : PubMed/NCBI
|
